CelLBxHealth plc (AIM:CLBX)

Market Cap	12.50M
Revenue (ttm)	2.62M
Net Income (ttm)	-15.78M
Shares Out	1.14B
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	636,389
Average Volume	3,307,707
Open	1.100
Previous Close	1.100
Day's Range	1.001 - 1.090
52-Week Range	1.000 - 17.445
Beta	0.14
RSI	39.95
Earnings Date	Dec 10, 2025

About CelLBxHealth

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytic...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1994
• Employees: 119
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CLBX

Financial Performance

In 2024, CelLBxHealth's revenue was 2.86 million, an increase of 30.92% compared to the previous year's 2.19 million. Losses were -14.23 million, -29.34% less than in 2023.